Sarepta Stock Drops 34% After Disappointing Earnings Report
Sarepta Therapeutics faced a significant setback as its stock plummeted 34% following the release of its latest earnings report. This sharp decline came after the biotechnology company revealed disappointing trial results for two of its treatments aimed at Duchenne muscular dystrophy (DMD), a rare and debilitating muscle-wasting disease. Investors were left questioning the timeline for…